
Cannabis and Cannabinoids (PDQ®)

Health Professional Version

Table of Contents

- Overview
- General Information
- History
- Laboratory/Animal/Preclinical Studies
 - Antitumor Effects
 - Appetite Stimulation
 - Analgesia
- Human/Clinical Studies
 - *Cannabis* Pharmacology
 - Cancer Risk
 - Cancer Treatment
 - Antiemetic Effect
 - Cannabinoids
 - *Cannabis*
 - Appetite Stimulation
 - Cannabinoids
 - *Cannabis*
 - Analgesia
 - Cannabinoids
 - *Cannabis*
 - Anxiety and Sleep
 - *Cannabis*
 - Current Clinical Trials
- Adverse Effects
 - *Cannabis* and Cannabinoids
- Summary of the Evidence for Cannabis and Cannabinoids
- Changes to This Summary (12/17/2014)
- About This PDQ Summary
 - Purpose of This Summary
 - Reviewers and Updates
 - Levels of Evidence
 - Permission to Use This Summary
 - Disclaimer

- [Contact Us](#)

Overview

This complementary and alternative medicine (CAM) information summary provides an overview of the use of *Cannabis* and its components as a treatment for people with cancer -related symptoms caused by the disease itself or its treatment.

This summary contains the following key information:

- *Cannabis* has been used for medicinal purposes for thousands of years.
- By federal law, the possession of *Cannabis*, also known as marijuana, is illegal in the United States; however, a growing number of states and the District of Columbia have enacted laws to legalize its medical use.
- The U.S. Food and Drug Administration has not approved *Cannabis* as a treatment for cancer or any other medical condition.
- Chemical components of *Cannabis*, called cannabinoids, activate specific receptors found throughout the body to produce pharmacologic effects, particularly in the central nervous system and the immune system.
- Commercially available cannabinoids, such as dronabinol and nabilone, are approved drugs for the treatment of cancer-related side effects.
- Cannabinoids may have benefits in the treatment of cancer-related side effects.

Many of the medical and scientific terms used in this summary are hypertext linked (at first use in each section) to the NCI Dictionary of Cancer Terms, which is oriented toward nonexperts. When a linked term is clicked, a definition will appear in a separate window.

Reference citations in some PDQ CAM information summaries may include links to external Web sites that are operated by individuals or organizations for the purpose of marketing or advocating the use of specific treatments or products. These reference citations are included for informational purposes only. Their inclusion should not be viewed as an endorsement of the content of the Web sites, or of any treatment or product, by the PDQ Cancer CAM Editorial Board or the National Cancer Institute.

General Information

Cannabis, also known as marijuana, originated in Central Asia but is grown worldwide today. In the United States, it is a controlled substance and is classified as a Schedule I agent (a drug with increased potential for abuse and no known medical use). The *Cannabis* plant produces a resin containing psychoactive compounds called cannabinoids. The highest concentration of cannabinoids is found in the female flowers of the plant.[1] Clinical trials conducted on medicinal *Cannabis* are limited. The U.S. Food and Drug Administration (FDA) has not approved the use of *Cannabis* as a treatment for any medical condition. To conduct clinical drug research in the United States, researchers must file an Investigational New Drug (IND) application with the FDA.

The potential benefits of medicinal *Cannabis* for people living with cancer include antiemetic effects, appetite stimulation, pain relief, and improved sleep. Although few relevant surveys of practice patterns exist, it appears that physicians caring for cancer patients in the United States who recommend medicinal *Cannabis* predominantly do so for symptom management.[2] A growing number of pediatric patients are seeking symptom relief with *Cannabis* or cannabinoid treatment, although studies are limited.

Cannabinoids are a group of terpenophenolic compounds found in *Cannabis* species (e.g., *Cannabis sativa* L.). This summary will review the role of *Cannabis* and the cannabinoids in the treatment of people with cancer and disease-related or treatment-related side effects.

References

1. Adams IB, Martin BR: Cannabis: pharmacology and toxicology in animals and humans. *Addiction* 91 (11): 1585-614, 1996. [PUBMED Abstract]
2. Doblin RE, Kleiman MA: Marijuana as antiemetic medicine: a survey of oncologists' experiences and attitudes. *J Clin Oncol* 9 (7): 1314-9, 1991. [PUBMED Abstract]

History

Cannabis use for medicinal purposes dates back at least 3,000 years.[1-5] It was introduced into Western medicine in the 1840s by W.B. O'Shaughnessy, a surgeon who learned of its medicinal properties while working in India for the British East Indies Company. Its use was promoted for reported analgesic, sedative, anti-inflammatory, antispasmodic, and anticonvulsant effects.

In 1937, the U.S. Treasury Department introduced the Marihuana Tax Act. This Act imposed a levy of \$1 per ounce for medicinal use of *Cannabis* and \$100 per ounce for recreational use. Physicians in the United States were the principal opponents of the Act. The American Medical Association (AMA) opposed the Act because physicians were required to pay a special tax for prescribing *Cannabis*, use special order forms to procure it, and keep special records concerning its professional use. In addition, the AMA believed that objective evidence that *Cannabis* was harmful was lacking and that passage of the Act would impede further research into its medicinal worth.[6] In 1942, *Cannabis* was removed from the U.S. Pharmacopoeia because of persistent concerns about its potential to cause harm.[2,3]

In 1951, Congress passed the Boggs Act, which for the first time, included *Cannabis* with narcotic drugs. In 1970, with the passage of the Controlled Substances Act, marijuana was classified as a Schedule I drug. Drugs in this category are distinguished as having no accepted medicinal use. Other Schedule I substances include heroin, LSD, mescaline, and methaqualone.

Despite its designation as having no medicinal use, *Cannabis* was distributed to patients by the U.S. government on a case-by-case basis under the Compassionate Use Investigational New Drug program established in 1978. Distribution of *Cannabis* through this program was discontinued in 1992.[1-4] Although federal law prohibits the use of *Cannabis*, the table below lists the localities that permit its use for certain medical conditions.

List of Localities That Permit Use of Cannabis for Certain Medical Conditions

Alaska (AK)
Arizona (AZ)
California (CA)
Colorado (CO)
Connecticut (CT)
Delaware (DE)
District of Columbia (DC)
Hawaii (HI)
Illinois (IL)
Maine (ME)
Maryland (MD)
Massachusetts (MA)
Michigan (MI)
Minnesota (MN)
Montana (MT)
Nevada (NV)
New Hampshire (NH)
New Jersey (NJ)
New Mexico (NM)

New York (NY)
Oregon (OR)
Rhode Island (RI)
Vermont (VT)
Washington (WA)

The main psychoactive constituent of *Cannabis* was identified as delta-9-tetrahydrocannabinol (THC). In 1986, synthetic delta-9-THC in sesame oil was licensed and approved for the treatment of chemotherapy - associated nausea and vomiting under the generic name dronabinol. Clinical trials determined that dronabinol was as effective as or better than other antiemetic agents available at the time.[7] Dronabinol was also studied for its ability to stimulate weight gain in patients with AIDS in the late 1980s. Thus, the indications were expanded to include treatment of anorexia associated with human immunodeficiency virus infection in 1992. Clinical trial results showed no statistically significant weight gain, although patients reported an improvement in appetite.[8,9]

Within the past 20 years, the neurobiology of cannabinoids has been analyzed.[10-13] The first cannabinoid receptor, CB1, was identified in the brain in 1988. A second cannabinoid receptor, CB2, was identified in 1993. The highest expression of CB2 receptors is located on B lymphocytes and natural killer cells, suggesting a possible role in immunity. Endogenous cannabinoids (endocannabinoids) have been identified and appear to have a role in, for example, pain modulation, control of movement, feeding behavior, and memory.[11]

Spasticity is a common symptom of multiple sclerosis for which existing therapy is unsatisfactory and may include muscle stiffness, reduced mobility, and pain. In Canada, New Zealand, and some countries in Europe, nabiximols (a THC:cannabidiol extract) is approved for the treatment of spasticity associated with multiple sclerosis via oromucosal administration.[14,15] Nabiximols is also approved in Canada (under the Notice of Compliance with Conditions) for symptomatic relief of pain in multiple sclerosis and advanced cancer.[15]

References

1. Abel EL: *Marihuana, The First Twelve Thousand Years*. New York: Plenum Press, 1980. Also available online. Last accessed November 5, 2014.
2. Joy JE, Watson SJ, Benson JA, eds.: *Marijuana and Medicine: Assessing the Science Base*. Washington, DC: National Academy Press, 1999. Also available online. Last accessed November 5, 2014.
3. Mack A, Joy J: *Marijuana As Medicine? The Science Beyond the Controversy*. Washington, DC: National Academy Press, 2001. Also available online. Last accessed November 5, 2014.
4. Booth M: *Cannabis: A History*. New York, NY: St Martin's Press, 2003.

5. Russo EB, Jiang HE, Li X, et al.: Phytochemical and genetic analyses of ancient cannabis from Central Asia. *J Exp Bot* 59 (15): 4171-82, 2008. [PUBMED Abstract]
6. Schaffer Library of Drug Policy: The Marihuana Tax Act of 1937: Taxation of Marihuana. Washington, DC: House of Representatives, Committee on Ways and Means, 1937. Available online. Last accessed November 5, 2014.
7. Sallan SE, Zinberg NE, Frei E 3rd: Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. *N Engl J Med* 293 (16): 795-7, 1975. [PUBMED Abstract]
8. Gorter R, Seefried M, Volberding P: Dronabinol effects on weight in patients with HIV infection. *AIDS* 6 (1): 127, 1992. [PUBMED Abstract]
9. Beal JE, Olson R, Laubenstein L, et al.: Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. *J Pain Symptom Manage* 10 (2): 89-97, 1995. [PUBMED Abstract]
10. Devane WA, Dysarz FA 3rd, Johnson MR, et al.: Determination and characterization of a cannabinoid receptor in rat brain. *Mol Pharmacol* 34 (5): 605-13, 1988. [PUBMED Abstract]
11. Devane WA, Hanus L, Breuer A, et al.: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. *Science* 258 (5090): 1946-9, 1992. [PUBMED Abstract]
12. Pertwee RG, Howlett AC, Abood ME, et al.: International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. *Pharmacol Rev* 62 (4): 588-631, 2010. [PUBMED Abstract]
13. Felder CC, Glass M: Cannabinoid receptors and their endogenous agonists. *Annu Rev Pharmacol Toxicol* 38: 179-200, 1998. [PUBMED Abstract]
14. Zajicek JP, Apostu VI: Role of cannabinoids in multiple sclerosis. *CNS Drugs* 25 (3): 187-201, 2011. [PUBMED Abstract]
15. Howard P, Twycross R, Shuster J, et al.: Cannabinoids. *J Pain Symptom Manage* 46 (1): 142-9, 2013. [PUBMED Abstract]

Laboratory/Animal/Preclinical Studies

Cannabinoids are a group of 21-carbon–containing terpenophenolic compounds produced uniquely by *Cannabis* species (e.g., *Cannabis sativa* L.).[1,2] These plant-derived compounds may be referred to as phytocannabinoids. Although delta-9-tetrahydrocannabinol (THC) is the primary psychoactive ingredient, other known compounds with biologic activity are cannabinal, cannabidiol (CBD), cannabichromene, cannabigerol, tetrahydrocannabivarin, and delta-8-THC. CBD, in particular, is thought to have significant analgesic and anti-inflammatory activity without the psychoactive effect (high) of delta-9-THC.

Antitumor Effects

One study in mice and rats suggested that cannabinoids may have a protective effect against the development of certain types of tumors.[3] During this 2-year study, groups of mice and rats were given various doses of THC by gavage. A dose-related decrease in the incidence of hepatic adenoma tumors and hepatocellular carcinoma (HCC) was observed in the mice. Decreased incidences of benign tumors (polyps and adenomas) in other organs (mammary gland, uterus, pituitary, testis, and pancreas) were also noted in the rats. In another study, delta-9-THC, delta-8-THC, and cannabinal were found to inhibit the growth of Lewis lung adenocarcinoma cells *in vitro* and *in vivo* .[4] In addition, other tumors have been shown to be

sensitive to cannabinoid-induced growth inhibition.[5-8]

Cannabinoids may cause antitumor effects by various mechanisms, including induction of cell death, inhibition of cell growth, and inhibition of tumor angiogenesis invasion and metastasis.[9-12] Two reviews summarize the molecular mechanisms of action of cannabinoids as antitumor agents.[13,14] Cannabinoids appear to kill tumor cells but do not affect their nontransformed counterparts and may even protect them from cell death. For example, these compounds have been shown to induce apoptosis in glioma cells in culture and induce regression of glioma tumors in mice and rats, while they protect normal glial cells of astroglial and oligodendroglial lineages from apoptosis mediated by the CB1 receptor.[9]

The effects of delta-9-THC and a synthetic agonist of the CB2 receptor were investigated in HCC.[15] Both agents reduced the viability of HCC cells *in vitro* and demonstrated antitumor effects in HCC subcutaneous xenografts in nude mice. The investigations documented that the anti-HCC effects are mediated by way of the CB2 receptor. Similar to findings in glioma cells, the cannabinoids were shown to trigger cell death through stimulation of an endoplasmic reticulum stress pathway that activates autophagy and promotes apoptosis. Other investigations have confirmed that CB1 and CB2 receptors may be potential targets in non-small cell lung carcinoma [16] and breast cancer.[17]

An *in vitro* study of the effect of CBD on programmed cell death in breast cancer cell lines found that CBD induced programmed cell death, independent of the CB1, CB2, or vanilloid receptors. CBD inhibited the survival of both estrogen receptor–positive and estrogen receptor–negative breast cancer cell lines, inducing apoptosis in a concentration-dependent manner while having little effect on nontumorigenic mammary cells.[18] Other studies have also shown the antitumor effect of cannabinoids (i.e., CBD and THC) in preclinical models of breast cancer.[19,20]

CBD has also been demonstrated to exert a chemopreventive effect in a mouse model of colon cancer.[21] In this experimental system, azoxymethane increased premalignant and malignant lesions in the mouse colon. Animals treated with azoxymethane and CBD concurrently were protected from developing premalignant and malignant lesions. In *in vitro* experiments involving colorectal cancer cell lines, the investigators found that CBD protected DNA from oxidative damage, increased endocannabinoid levels, and reduced cell proliferation. In a subsequent study, the investigators found that the antiproliferative effect of CBD was counteracted by selective CB1 but not CB2 receptor antagonists, suggesting an involvement of CB1 receptors.[22]

Another investigation into the antitumor effects of CBD examined the role of intercellular adhesion molecule-1 (ICAM-1).[12] ICAM-1 expression has been reported to be negatively correlated with cancer metastasis. In lung cancer cell lines, CBD upregulated ICAM-1, leading to decreased cancer cell invasiveness.

In an *in vivo* model using severe combined immunodeficient mice, subcutaneous tumors were generated by inoculating the animals with cells from human non-small cell lung carcinoma cell lines.[23] Tumor growth was inhibited by 60% in THC-treated mice compared with vehicle-treated control mice. Tumor specimens revealed that THC had antiangiogenic and antiproliferative effects. However, research with immunocompetent murine tumor models has demonstrated immunosuppression and enhanced tumor growth in mice treated with THC.[24,25]

In addition, both plant-derived and endogenous cannabinoids have been studied for anti-inflammatory effects. A mouse study demonstrated that endogenous cannabinoid system signaling is likely to provide intrinsic protection against colonic inflammation.[26] As a result, a hypothesis that phytocannabinoids and endocannabinoids may be useful in the risk reduction and treatment of colorectal cancer has been developed.[27-30]

CBD may also enhance uptake of cytotoxic drugs into malignant cells. Activation of the transient receptor potential vanilloid type 2 (TRPV2) has been shown to inhibit proliferation of human glioblastoma multiforme cells and overcome resistance to the chemotherapy agent carmustine.[31] In an *in vitro* model, CBD increased TRPV2 activation and increased uptake of cytotoxic drugs, leading to apoptosis of glioma cells without affecting normal human astrocytes. This suggests that coadministration of CBD with cytotoxic agents may increase drug uptake and potentiate cell death in human glioma cells. Also, CBD together with THC may enhance the antitumor activity of classic chemotherapeutic drugs such as temozolomide in some mouse models of cancer.[13,32]

Appetite Stimulation

Many animal studies have previously demonstrated that delta-9-THC and other cannabinoids have a stimulatory effect on appetite and increase food intake. It is believed that the endogenous cannabinoid system may serve as a regulator of feeding behavior. The endogenous cannabinoid anandamide potently enhances appetite in mice.[33] Moreover, CB1 receptors in the hypothalamus may be involved in the motivational or reward aspects of eating.[34]

Analgesia

Understanding the mechanism of cannabinoid-induced analgesia has been increased through the study of cannabinoid receptors, endocannabinoids, and synthetic agonists and antagonists. The CB1 receptor is found in both the central nervous system (CNS) and in peripheral nerve terminals. Similar to opioid receptors, increased levels of the CB1 receptor are found in regions of the brain that regulate nociceptive processing.[35] CB2 receptors, located predominantly in peripheral tissue, exist at very low levels in the CNS. With the development of receptor-specific antagonists, additional information about the roles of the receptors and endogenous cannabinoids in the modulation of pain has been obtained.[36,37]

Cannabinoids may also contribute to pain modulation through an anti-inflammatory mechanism; a CB2 effect with cannabinoids acting on mast cell receptors to attenuate the release of inflammatory agents, such as histamine and serotonin, and on keratinocytes to enhance the release of analgesic opioids has been described.[38-40] One study reported that the efficacy of synthetic CB1- and CB2-receptor agonists were comparable with the efficacy of morphine in a murine model of tumor pain.[41]

References

1. Adams IB, Martin BR: Cannabis: pharmacology and toxicology in animals and humans. *Addiction* 91 (11): 1585-614, 1996. [PUBMED Abstract]

2. Grotenhermen F, Russo E, eds.: *Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential*. Binghamton, NY: The Haworth Press, 2002.
3. National Toxicology Program: NTP toxicology and carcinogenesis studies of 1-trans-delta(9)-tetrahydrocannabinol (CAS No. 1972-08-3) in F344 rats and B6C3F1 mice (gavage studies). *Natl Toxicol Program Tech Rep Ser* 446 (0): 1-317, 1996. [PUBMED Abstract]
4. Bifulco M, Laezza C, Pisanti S, et al.: Cannabinoids and cancer: pros and cons of an antitumour strategy. *Br J Pharmacol* 148 (2): 123-35, 2006. [PUBMED Abstract]
5. Sánchez C, de Ceballos ML, Gomez del Pulgar T, et al.: Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. *Cancer Res* 61 (15): 5784-9, 2001. [PUBMED Abstract]
6. McKallip RJ, Lombard C, Fisher M, et al.: Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. *Blood* 100 (2): 627-34, 2002. [PUBMED Abstract]
7. Casanova ML, Blázquez C, Martínez-Palacio J, et al.: Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. *J Clin Invest* 111 (1): 43-50, 2003. [PUBMED Abstract]
8. Blázquez C, González-Feria L, Alvarez L, et al.: Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. *Cancer Res* 64 (16): 5617-23, 2004. [PUBMED Abstract]
9. Guzmán M: Cannabinoids: potential anticancer agents. *Nat Rev Cancer* 3 (10): 745-55, 2003. [PUBMED Abstract]
10. Blázquez C, Casanova ML, Planas A, et al.: Inhibition of tumor angiogenesis by cannabinoids. *FASEB J* 17 (3): 529-31, 2003. [PUBMED Abstract]
11. Vaccani A, Massi P, Colombo A, et al.: Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. *Br J Pharmacol* 144 (8): 1032-6, 2005. [PUBMED Abstract]
12. Ramer R, Bublitz K, Freimuth N, et al.: Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1. *FASEB J* 26 (4): 1535-48, 2012. [PUBMED Abstract]
13. Velasco G, Sánchez C, Guzmán M: Towards the use of cannabinoids as antitumour agents. *Nat Rev Cancer* 12 (6): 436-44, 2012. [PUBMED Abstract]
14. Cridge BJ, Rosengren RJ: Critical appraisal of the potential use of cannabinoids in cancer management. *Cancer Manag Res* 5: 301-13, 2013. [PUBMED Abstract]
15. Vara D, Salazar M, Olea-Herrero N, et al.: Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy. *Cell Death Differ* 18 (7): 1099-111, 2011. [PUBMED Abstract]
16. Preet A, Qamri Z, Nasser MW, et al.: Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis. *Cancer Prev Res (Phila)* 4 (1): 65-75, 2011. [PUBMED Abstract]
17. Nasser MW, Qamri Z, Deol YS, et al.: Crosstalk between chemokine receptor CXCR4 and cannabinoid receptor CB2 in modulating breast cancer growth and invasion. *PLoS One* 6 (9): e23901, 2011. [PUBMED Abstract]
18. Shrivastava A, Kuzontkoski PM, Groopman JE, et al.: Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. *Mol Cancer Ther* 10 (7): 1161-72, 2011. [PUBMED Abstract]
19. Caffarel MM, Andradas C, Mira E, et al.: Cannabinoids reduce ErbB2-driven breast cancer

- progression through Akt inhibition. *Mol Cancer* 9: 196, 2010. [PUBMED Abstract]
20. McAllister SD, Murase R, Christian RT, et al.: Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. *Breast Cancer Res Treat* 129 (1): 37-47, 2011. [PUBMED Abstract]
 21. Aviello G, Romano B, Borrelli F, et al.: Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer. *J Mol Med (Berl)* 90 (8): 925-34, 2012. [PUBMED Abstract]
 22. Romano B, Borrelli F, Pagano E, et al.: Inhibition of colon carcinogenesis by a standardized *Cannabis sativa* extract with high content of cannabidiol. *Phytomedicine* 21 (5): 631-9, 2014. [PUBMED Abstract]
 23. Preet A, Ganju RK, Groopman JE: Delta9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. *Oncogene* 27 (3): 339-46, 2008. [PUBMED Abstract]
 24. Zhu LX, Sharma S, Stolina M, et al.: Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. *J Immunol* 165 (1): 373-80, 2000. [PUBMED Abstract]
 25. McKallip RJ, Nagarkatti M, Nagarkatti PS: Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. *J Immunol* 174 (6): 3281-9, 2005. [PUBMED Abstract]
 26. Massa F, Marsicano G, Hermann H, et al.: The endogenous cannabinoid system protects against colonic inflammation. *J Clin Invest* 113 (8): 1202-9, 2004. [PUBMED Abstract]
 27. Patsos HA, Hicks DJ, Greenhough A, et al.: Cannabinoids and cancer: potential for colorectal cancer therapy. *Biochem Soc Trans* 33 (Pt 4): 712-4, 2005. [PUBMED Abstract]
 28. Liu WM, Fowler DW, Dalglish AG: Cannabis-derived substances in cancer therapy--an emerging anti-inflammatory role for the cannabinoids. *Curr Clin Pharmacol* 5 (4): 281-7, 2010. [PUBMED Abstract]
 29. Malfitano AM, Ciaglia E, Gangemi G, et al.: Update on the endocannabinoid system as an anticancer target. *Expert Opin Ther Targets* 15 (3): 297-308, 2011. [PUBMED Abstract]
 30. Sarfaraz S, Adhami VM, Syed DN, et al.: Cannabinoids for cancer treatment: progress and promise. *Cancer Res* 68 (2): 339-42, 2008. [PUBMED Abstract]
 31. Nabissi M, Morelli MB, Santoni M, et al.: Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents. *Carcinogenesis* 34 (1): 48-57, 2013. [PUBMED Abstract]
 32. Torres S, Lorente M, Rodríguez-Fornés F, et al.: A combined preclinical therapy of cannabinoids and temozolomide against glioma. *Mol Cancer Ther* 10 (1): 90-103, 2011. [PUBMED Abstract]
 33. Mechoulam R, Berry EM, Avraham Y, et al.: Endocannabinoids, feeding and suckling--from our perspective. *Int J Obes (Lond)* 30 (Suppl 1): S24-8, 2006. [PUBMED Abstract]
 34. Fride E, Bregman T, Kirkham TC: Endocannabinoids and food intake: newborn suckling and appetite regulation in adulthood. *Exp Biol Med (Maywood)* 230 (4): 225-34, 2005. [PUBMED Abstract]
 35. Walker JM, Hohmann AG, Martin WJ, et al.: The neurobiology of cannabinoid analgesia. *Life Sci* 65 (6-7): 665-73, 1999. [PUBMED Abstract]
 36. Meng ID, Manning BH, Martin WJ, et al.: An analgesia circuit activated by cannabinoids. *Nature* 395 (6700): 381-3, 1998. [PUBMED Abstract]

37. Walker JM, Huang SM, Strangman NM, et al.: Pain modulation by release of the endogenous cannabinoid anandamide. *Proc Natl Acad Sci U S A* 96 (21): 12198-203, 1999. [PUBMED Abstract]
38. Facci L, Dal Toso R, Romanello S, et al.: Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. *Proc Natl Acad Sci U S A* 92 (8): 3376-80, 1995. [PUBMED Abstract]
39. Ibrahim MM, Porreca F, Lai J, et al.: CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. *Proc Natl Acad Sci U S A* 102 (8): 3093-8, 2005. [PUBMED Abstract]
40. Richardson JD, Kilo S, Hargreaves KM: Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. *Pain* 75 (1): 111-9, 1998. [PUBMED Abstract]
41. Khasabova IA, Gielissen J, Chandiramani A, et al.: CB1 and CB2 receptor agonists promote analgesia through synergy in a murine model of tumor pain. *Behav Pharmacol* 22 (5-6): 607-16, 2011. [PUBMED Abstract]

Human/Clinical Studies

***Cannabis* Pharmacology**

When *Cannabis* is ingested by mouth, there is a low (6%–20%) and variable oral bioavailability.[1,2] Peak plasma concentrations of delta-9-tetrahydrocannabinol (THC) occur after 1 to 6 hours and remain elevated with a terminal half-life of 20 to 30 hours. Taken by mouth, delta-9-THC is initially metabolized in the liver to 11-OH-THC, a potent psychoactive metabolite. When inhaled, cannabinoids are rapidly absorbed into the bloodstream with a peak concentration in 2 to 10 minutes, declining rapidly for a period of 30 minutes and with less generation of the psychoactive 11-OH metabolite.

Cannabinoids are known to interact with the hepatic cytochrome P450 enzyme system.[3,4] In one study, 24 cancer patients were treated with intravenous irinotecan (600 mg, n = 12) or docetaxel (180 mg, n = 12), followed 3 weeks later by the same drugs concomitant with medicinal *Cannabis* taken in the form of an herbal tea for 15 consecutive days, starting 12 days before the second treatment.[4] The administration of *Cannabis* did not significantly influence exposure to and clearance of irinotecan or docetaxel, although the herbal tea route of administration may not reproduce the effects of inhalation or oral ingestion of fat-soluble cannabinoids.

Cancer Risk

A number of studies have yielded conflicting evidence regarding the risks of various cancers associated with *Cannabis* use.

A pooled analysis of three case-cohort studies of men in northwestern Africa (430 cases and 778 controls) showed a significantly increased risk of lung cancer among tobacco smokers who also inhaled *Cannabis*.[5]

A large, retrospective cohort study of 64,855 men aged 15 to 49 years from the United States found that *Cannabis* use was not associated with tobacco-related cancers and a number of other common malignancies. However, the study did find that, among nonsmokers of tobacco, ever having used *Cannabis*

was associated with an increased risk of prostate cancer.[6]

A population-based case-control study of 611 lung cancer patients revealed that chronic low *Cannabis* exposure was not associated with an increased risk of lung cancer or other upper aerodigestive tract cancers and found no positive associations with any cancer type (oral, pharyngeal, laryngeal, lung, or esophagus) when adjusting for several confounders, including cigarette smoking.[7]

A systematic review assessing 19 studies that evaluated premalignant or malignant lung lesions in persons 18 years or older who inhaled marijuana concluded that observational studies failed to demonstrate statistically significant associations between marijuana inhalation and lung cancer after adjusting for tobacco use.[8]

Epidemiologic studies examining one association of *Cannabis* use with head and neck squamous cell carcinomas have also been inconsistent in their findings. A pooled analysis of nine case-control studies from the U.S./Latin American International Head and Neck Cancer Epidemiology (INHANCE) Consortium included information from 1,921 oropharyngeal cases, 356 tongue cases, and 7,639 controls. Compared with those who never smoked *Cannabis*, *Cannabis* smokers had an elevated risk of oropharyngeal cancers and a reduced risk of tongue cancer. These study results both reflect the inconsistent effects of cannabinoids on cancer incidence noted in previous studies and suggest that more work needs to be done to understand the potential role of human papillomavirus infection.[9]

With a hypothesis that chronic marijuana use produces adverse effects on the human endocrine and reproductive systems, the association between marijuana use and incidence of testicular germ cell tumors (TGCTs) has been examined.[10-12] Three population-based case-control studies report an association between marijuana use and elevated risk of TGCTs, especially nonseminoma or mixed-histology tumors. [10-12] However, the sample sizes in these studies were inadequate to address marijuana dose by addressing associations with respect to recency, frequency, and duration of use. These early reports of marijuana use and TGCTs establish the need for larger, well-powered, prospective studies, especially studies evaluating the role of endocannabinoid signaling and cannabinoid receptors in TGCTs.

A comprehensive Health Canada monograph on marijuana concluded that while there are many cellular and molecular studies that provide strong evidence that inhaled marijuana is carcinogenic, the epidemiologic evidence of a link between marijuana use and cancer is still inconclusive.[13]

Cancer Treatment

No clinical trials of *Cannabis* as a treatment for cancer in humans were identified in a PubMed search; however, a single, small study of intratumoral injection of delta-9-THC in patients with recurrent glioblastoma multiforme reported potential antitumoral activity.[14,15]

Antiemetic Effect

Cannabinoids

Despite advances in pharmacologic and nonpharmacologic management, nausea and vomiting (N/V)

remain distressing side effects for cancer patients and their families. Dronabinol, a synthetically produced delta-9-THC, was approved in the United States in 1986 as an antiemetic to be used in cancer chemotherapy. Nabilone, a synthetic derivative of delta-9-THC, was first approved in Canada in 1982 and is now also available in the United States.[16] Both dronabinol and nabilone have been approved by the U.S. Food and Drug Administration for the treatment of N/V associated with cancer chemotherapy in patients who have failed to respond to conventional antiemetic therapy. Numerous clinical trials and meta-analyses have shown that dronabinol and nabilone are effective in the treatment of N/V induced by chemotherapy.[17-20] The National Comprehensive Cancer Network Guidelines recommend cannabinoids as breakthrough treatment for chemotherapy-related N/V.

One systematic review studied 30 randomized comparisons of delta-9-THC preparations with placebo or other antiemetics from which data on efficacy and harm were available.[21] Oral nabilone, oral dronabinol, and intramuscular levonantradol (a synthetic analog of dronabinol) were tested. Inhaled *Cannabis* trials were not included. Among all 1,366 patients included in the review, cannabinoids were found to be more effective than the conventional antiemetics prochlorperazine, metoclopramide, chlorpromazine, thiethylperazine, haloperidol, domperidone, and alizapride. Cannabinoids, however, were not more effective for patients receiving very low or very high emetogenic chemotherapy. Side effects included a feeling of being high, euphoria, sedation or drowsiness, dizziness, dysphoria or depression, hallucinations, paranoia, and hypotension.[21] Newer antiemetics (e.g., 5-HT₃ receptor antagonists) have not been directly compared with *Cannabis* or cannabinoids in cancer patients.

Another analysis of 15 controlled studies compared nabilone with placebo or available antiemetic drugs.[22] Among 600 cancer patients, nabilone was found to be superior to prochlorperazine, domperidone, and alizapride, with nabilone favored for continuous use.

(Refer to the *Cannabis* section in the PDQ summary on Nausea and Vomiting for more information.)

Cannabis

Three trials have evaluated the efficacy of inhaled marijuana in chemotherapy-induced N/V.[23-25] In two of the studies, inhaled *Cannabis* was made available only after dronabinol failure. In the first trial, no antiemetic effect was achieved with marijuana in patients receiving cyclophosphamide or doxorubicin,[23] but in the second trial, a statistically significant superior antiemetic effect of inhaled *Cannabis* versus placebo was found among patients receiving high-dose methotrexate.[24] The third trial was a randomized, double-blind, placebo-controlled, cross-over trial involving 20 adults in which both inhaled marijuana and oral THC were evaluated. One-quarter of the patients reported a favorable antiemetic response to the cannabinoid therapies. This latter study was reported in abstract form in 1984. A full report, detailing the methods and outcomes apparently has not been published, which limits a thorough interpretation of the significance of these findings.[25]

Appetite Stimulation

Anorexia, early satiety, weight loss, and cachexia are problems experienced by cancer patients. Such patients are faced not only with the disfigurement associated with wasting but also with an inability to engage in the social interaction of meals.

Cannabinoids

Three controlled trials demonstrated that oral THC has variable effects on appetite stimulation and weight loss in patients with advanced malignancies and human immunodeficiency virus (HIV) infection.[22] One study evaluated whether dronabinol alone or with megestrol acetate was greater, less, or equal in efficacy to megestrol acetate alone for managing cancer-associated anorexia.[26] In this randomized, double-blind study of 469 adults with advanced cancer and weight loss, patients received 2.5 mg of oral THC twice daily, 800 mg of oral megestrol daily, or both. Appetite increased by 75% in the megestrol group and weight increased by 11%, compared with a 49% increase in appetite and a 3% increase in weight in the oral THC group after 8 to 11 weeks of treatment. These two differences were statistically significant. Furthermore, the combined therapy did not offer additional benefits beyond those provided by megestrol acetate alone. The authors concluded that dronabinol did little to promote appetite or weight gain in advanced cancer patients compared with megestrol acetate. However, a smaller, placebo-controlled trial of dronabinol in cancer patients demonstrated improved and enhanced chemosensory perception in the cannabinoid group—food tasted better, appetite increased, and the proportion of calories consumed as protein was greater than in the placebo recipients.[27]

In a randomized clinical trial, researchers compared the safety and effectiveness of orally administered *Cannabis* extract (2.5 mg THC and 1 mg cannabidiol), THC (2.5 mg), or placebo for the treatment of cancer-related anorexia-cachexia in 243 patients with advanced cancer who received treatment twice daily for 6 weeks. Results demonstrated that although these agents were well tolerated by these patients, no differences were observed in patient appetite or quality of life among the three groups at this dose level and duration of intervention.[28]

Another clinical trial that involved 139 patients with HIV or AIDS and weight loss found that, compared with placebo, oral dronabinol was associated with a statistically significant increase in appetite after 4 to 6 weeks of treatment. Patients receiving dronabinol tended to have weight stabilization, whereas patients receiving placebo continued to lose weight.[29]

Cannabis

In trials conducted in the 1980s that involved healthy control subjects, inhaling *Cannabis* led to an increase in caloric intake, mainly in the form of between-meal snacks, with increased intakes of fatty and sweet foods.[30,31] No published studies have explored the effect of inhaled *Cannabis* on appetite in cancer patients.

Analgesia

Cannabinoids

Pain management improves a patient's quality of life throughout all stages of cancer. Through the study of cannabinoid receptors, endocannabinoids, and synthetic agonists and antagonists, the mechanisms of cannabinoid-induced analgesia have been analyzed. The CB1 receptor is found in the central nervous system (CNS) and in peripheral nerve terminals.[32] CB2 receptors are located mainly in peripheral tissue and are expressed in only low amounts in the CNS. Whereas only CB1 agonists exert analgesic activity in

the CNS, both CB1 and CB2 agonists have analgesic activity in peripheral tissue.[33,34]

Cancer pain results from inflammation, invasion of bone or other pain-sensitive structures, or nerve injury. When cancer pain is severe and persistent, it is often resistant to treatment with opioids.

Two studies examined the effects of oral delta-9-THC on cancer pain. The first, a double-blind placebo-controlled study involving ten patients, measured both pain intensity and pain relief.[35] It was reported that 15 mg and 20 mg doses of the cannabinoid delta-9-THC were associated with substantial analgesic effects, with antiemetic effects and appetite stimulation.

In a follow-up, single-dose study involving 36 patients, it was reported that 10 mg doses of delta-9-THC produced analgesic effects during a 7-hour observation period that were comparable to 60 mg doses of codeine, and 20 mg doses of delta-9-THC induced effects equivalent to 120 mg doses of codeine.[36] Higher doses of THC were found to be more sedative than codeine.

Another study examined the effects of a whole-plant extract with controlled cannabinoid content in an oromucosal spray. In a multicenter, double-blind, placebo-controlled study, the THC:cannabidiol nabiximols (THC:CBD) extract and THC extract alone were compared in the analgesic management of patients with advanced cancer and with moderate-to-severe cancer-related pain. Patients were assigned to one of three treatment groups: THC:CBD extract, THC extract, or placebo. The researchers concluded that the THC:CBD extract was efficacious for pain relief in advanced cancer patients whose pain was not fully relieved by strong opioids.[37] In a randomized, placebo-controlled, graded-dose trial, opioid-treated cancer patients with poorly controlled chronic pain demonstrated significantly better control of pain and sleep disruption with THC:CBD oromucosal spray at lower doses (1–4 and 6–10 sprays/day), compared with placebo. Adverse events were dose related, with only the high-dose group (11–16 sprays/day) comparing unfavorably with the placebo arm. These studies provide promising evidence of an “adjuvant analgesic” effect of THC:CBD in this opioid-refractory patient population and may provide an opportunity to address this significant clinical challenge.[38] An open-label extension study of 43 patients who had participated in the randomized trial found that some patients continued to obtain relief of their cancer-related pain with long-term use of the THC:CBD oromucosal spray without increasing their dose of the spray or the dose of their other analgesics.[39]

A randomized, placebo-controlled, crossover pilot study of nabiximols in 16 patients with chemotherapy-induced neuropathic pain showed no significant difference between the treatment and placebo groups. A responder analysis, however, demonstrated that five patients reported a reduction in their pain of at least 2 points, suggesting that a larger follow-up study may be warranted.[40]

An observational study assessed the effectiveness of nabilone in advanced cancer patients who were experiencing pain and other symptoms (anorexia, depression, and anxiety). The researchers reported that patients who used nabilone experienced improved management of pain, nausea, anxiety, and distress when compared with untreated patients. Nabilone was also associated with a decreased use of opioids, nonsteroidal anti-inflammatory drugs, tricyclic antidepressants, gabapentin, dexamethasone, metoclopramide, and ondansetron.[41]

Cannabis

Animal studies have suggested a synergistic analgesic effect when cannabinoids are combined with opioids. The results from one pharmacokinetic interaction study have been reported. In this study, 21 patients with chronic pain were administered vaporized *Cannabis* along with sustained-release morphine or oxycodone for 5 days.[42] The patients who received vaporized *Cannabis* and sustained-release morphine had a statistically significant decrease in their mean pain score over the 5-day period; those who received vaporized *Cannabis* and oxycodone did not. These findings should be verified by further studies before recommendations favoring such an approach are warranted in general clinical practice.

Neuropathic pain is a symptom cancer patients may experience, especially if treated with platinum-based chemotherapy or taxanes. To date, no clinical trial has examined the effectiveness of cannabinoid preparations in the treatment of chemotherapy-induced neuropathic pain.

Two randomized controlled trials of inhaled *Cannabis* in patients with peripheral neuropathy or neuropathic pain of various etiologies found that pain was reduced in patients who received inhaled *Cannabis*, compared with those who received placebo.[43,44] Two additional trials of inhaled *Cannabis* have also demonstrated the benefit of *Cannabis* over placebo in HIV-associated neuropathic pain.[45,46]

Anxiety and Sleep

Cannabis

Patients often experience mood elevation after exposure to *Cannabis*, depending on their prior experience. In a five-patient case series of inhaled marijuana that examined the analgesic effects of THC, it was reported that patients administered THC had improved mood, improved sense of well-being, and less anxiety.[47]

Another common effect of *Cannabis* is sleepiness. In a trial of a sublingual spray, a *Cannabis*-based mixture was able to improve sleep quality.[48] A small placebo-controlled study of dronabinol in cancer patients with altered chemosensory perception also noted increased quality of sleep and relaxation in THC-treated patients.[27]

Current Clinical Trials

Check NCI's list of cancer clinical trials for cancer CAM clinical trials on dronabinol, marijuana, nabiximols and nabilone that are actively enrolling patients.

General information about clinical trials is also available from the NCI Web site.

References

1. Adams IB, Martin BR: Cannabis: pharmacology and toxicology in animals and humans. *Addiction* 91 (11): 1585-614, 1996. [PUBMED Abstract]
2. Agurell S, Halldin M, Lindgren JE, et al.: Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. *Pharmacol Rev* 38 (1): 21-43,

1986. [PUBMED Abstract]
3. Yamamoto I, Watanabe K, Narimatsu S, et al.: Recent advances in the metabolism of cannabinoids. *Int J Biochem Cell Biol* 27 (8): 741-6, 1995. [PUBMED Abstract]
 4. Engels FK, de Jong FA, Sparreboom A, et al.: Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel. *Oncologist* 12 (3): 291-300, 2007. [PUBMED Abstract]
 5. Berthiller J, Straif K, Boniol M, et al.: Cannabis smoking and risk of lung cancer in men: a pooled analysis of three studies in Maghreb. *J Thorac Oncol* 3 (12): 1398-403, 2008. [PUBMED Abstract]
 6. Sidney S, Quesenberry CP Jr, Friedman GD, et al.: Marijuana use and cancer incidence (California, United States). *Cancer Causes Control* 8 (5): 722-8, 1997. [PUBMED Abstract]
 7. Hashibe M, Morgenstern H, Cui Y, et al.: Marijuana use and the risk of lung and upper aerodigestive tract cancers: results of a population-based case-control study. *Cancer Epidemiol Biomarkers Prev* 15 (10): 1829-34, 2006. [PUBMED Abstract]
 8. Mehra R, Moore BA, Crothers K, et al.: The association between marijuana smoking and lung cancer: a systematic review. *Arch Intern Med* 166 (13): 1359-67, 2006. [PUBMED Abstract]
 9. Marks MA, Chaturvedi AK, Kelsey K, et al.: Association of marijuana smoking with oropharyngeal and oral tongue cancers: pooled analysis from the INHANCE consortium. *Cancer Epidemiol Biomarkers Prev* 23 (1): 160-71, 2014. [PUBMED Abstract]
 10. Daling JR, Doody DR, Sun X, et al.: Association of marijuana use and the incidence of testicular germ cell tumors. *Cancer* 115 (6): 1215-23, 2009. [PUBMED Abstract]
 11. Trabert B, Sigurdson AJ, Sweeney AM, et al.: Marijuana use and testicular germ cell tumors. *Cancer* 117 (4): 848-53, 2011. [PUBMED Abstract]
 12. Lacson JC, Carroll JD, Tuazon E, et al.: Population-based case-control study of recreational drug use and testis cancer risk confirms an association between marijuana use and nonseminoma risk. *Cancer* 118 (21): 5374-83, 2012. [PUBMED Abstract]
 13. Health Canada: Marijuana (Marijuana, Cannabis): Dried Plant for Administration by Ingestion or Other Means. Ottawa, Canada: Health Canada, 2010. Available online. Last accessed November 5, 2014.
 14. Guzmán M, Duarte MJ, Blázquez C, et al.: A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. *Br J Cancer* 95 (2): 197-203, 2006. [PUBMED Abstract]
 15. Velasco G, Sánchez C, Guzmán M: Towards the use of cannabinoids as antitumour agents. *Nat Rev Cancer* 12 (6): 436-44, 2012. [PUBMED Abstract]
 16. Sutton IR, Daeninck P: Cannabinoids in the management of intractable chemotherapy-induced nausea and vomiting and cancer-related pain. *J Support Oncol* 4 (10): 531-5, 2006 Nov-Dec. [PUBMED Abstract]
 17. Ahmedzai S, Carlyle DL, Calder IT, et al.: Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. *Br J Cancer* 48 (5): 657-63, 1983. [PUBMED Abstract]
 18. Chan HS, Correia JA, MacLeod SM: Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial. *Pediatrics* 79 (6): 946-52, 1987. [PUBMED Abstract]
 19. Johansson R, Kilkku P, Groenroos M: A double-blind, controlled trial of nabilone vs. prochlorperazine for refractory emesis induced by cancer chemotherapy. *Cancer Treat Rev* 9 (Suppl

- B): 25-33, 1982. [PUBMED Abstract]
20. Niiranen A, Mattson K: A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy. *Am J Clin Oncol* 8 (4): 336-40, 1985. [PUBMED Abstract]
 21. Tramèr MR, Carroll D, Campbell FA, et al.: Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. *BMJ* 323 (7303): 16-21, 2001. [PUBMED Abstract]
 22. Ben Amar M: Cannabinoids in medicine: A review of their therapeutic potential. *J Ethnopharmacol* 105 (1-2): 1-25, 2006. [PUBMED Abstract]
 23. Chang AE, Shiling DJ, Stillman RC, et al.: A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. *Cancer* 47 (7): 1746-51, 1981. [PUBMED Abstract]
 24. Chang AE, Shiling DJ, Stillman RC, et al.: Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation. *Ann Intern Med* 91 (6): 819-24, 1979. [PUBMED Abstract]
 25. Levitt M, Faiman C, Hawks R, et al.: Randomized double blind comparison of delta-9-tetrahydrocannabinol and marijuana as chemotherapy antiemetics. [Abstract] *Proceedings of the American Society of Clinical Oncology* 3: A-C354, 91, 1984.
 26. Jatoi A, Windschitl HE, Loprinzi CL, et al.: Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. *J Clin Oncol* 20 (2): 567-73, 2002. [PUBMED Abstract]
 27. Brisbois TD, de Kock IH, Watanabe SM, et al.: Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. *Ann Oncol* 22 (9): 2086-93, 2011. [PUBMED Abstract]
 28. Strasser F, Luftner D, Possinger K, et al.: Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. *J Clin Oncol* 24 (21): 3394-400, 2006. [PUBMED Abstract]
 29. Beal JE, Olson R, Laubenstein L, et al.: Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. *J Pain Symptom Manage* 10 (2): 89-97, 1995. [PUBMED Abstract]
 30. Foltin RW, Brady JV, Fischman MW: Behavioral analysis of marijuana effects on food intake in humans. *Pharmacol Biochem Behav* 25 (3): 577-82, 1986. [PUBMED Abstract]
 31. Foltin RW, Fischman MW, Byrne MF: Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory. *Appetite* 11 (1): 1-14, 1988. [PUBMED Abstract]
 32. Walker JM, Hohmann AG, Martin WJ, et al.: The neurobiology of cannabinoid analgesia. *Life Sci* 65 (6-7): 665-73, 1999. [PUBMED Abstract]
 33. Calignano A, La Rana G, Giuffrida A, et al.: Control of pain initiation by endogenous cannabinoids. *Nature* 394 (6690): 277-81, 1998. [PUBMED Abstract]
 34. Fields HL, Meng ID: Watching the pot boil. *Nat Med* 4 (9): 1008-9, 1998. [PUBMED Abstract]
 35. Noyes R Jr, Brunk SF, Baram DA, et al.: Analgesic effect of delta-9-tetrahydrocannabinol. *J Clin Pharmacol* 15 (2-3): 139-43, 1975 Feb-Mar. [PUBMED Abstract]
 36. Noyes R Jr, Brunk SF, Avery DA, et al.: The analgesic properties of delta-9-tetrahydrocannabinol and codeine. *Clin Pharmacol Ther* 18 (1): 84-9, 1975. [PUBMED Abstract]
 37. Johnson JR, Burnell-Nugent M, Lossignol D, et al.: Multicenter, double-blind, randomized, placebo-

- controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. *J Pain Symptom Manage* 39 (2): 167-79, 2010. [PUBMED Abstract]
38. Portenoy RK, Ganae-Motan ED, Allende S, et al.: Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. *J Pain* 13 (5): 438-49, 2012. [PUBMED Abstract]
 39. Johnson JR, Lossignol D, Burnell-Nugent M, et al.: An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. *J Pain Symptom Manage* 46 (2): 207-18, 2013. [PUBMED Abstract]
 40. Lynch ME, Cesar-Rittenberg P, Hohmann AG: A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. *J Pain Symptom Manage* 47 (1): 166-73, 2014. [PUBMED Abstract]
 41. Maida V, Ennis M, Irani S, et al.: Adjunctive nabilone in cancer pain and symptom management: a prospective observational study using propensity scoring. *J Support Oncol* 6 (3): 119-24, 2008. [PUBMED Abstract]
 42. Abrams DI, Couey P, Shade SB, et al.: Cannabinoid-opioid interaction in chronic pain. *Clin Pharmacol Ther* 90 (6): 844-51, 2011. [PUBMED Abstract]
 43. Wilsey B, Marcotte T, Deutsch R, et al.: Low-dose vaporized cannabis significantly improves neuropathic pain. *J Pain* 14 (2): 136-48, 2013. [PUBMED Abstract]
 44. Wilsey B, Marcotte T, Tsodikov A, et al.: A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. *J Pain* 9 (6): 506-21, 2008. [PUBMED Abstract]
 45. Abrams DI, Jay CA, Shade SB, et al.: Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. *Neurology* 68 (7): 515-21, 2007. [PUBMED Abstract]
 46. Ellis RJ, Toperoff W, Vaida F, et al.: Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. *Neuropsychopharmacology* 34 (3): 672-80, 2009. [PUBMED Abstract]
 47. Noyes R Jr, Baram DA: Cannabis analgesia. *Compr Psychiatry* 15 (6): 531-5, 1974 Nov-Dec. [PUBMED Abstract]
 48. Russo EB, Guy GW, Robson PJ: Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine. *Chem Biodivers* 4 (8): 1729-43, 2007. [PUBMED Abstract]

Adverse Effects

***Cannabis* and Cannabinoids**

Because cannabinoid receptors, unlike opioid receptors, are not located in the brainstem areas controlling respiration, lethal overdoses from *Cannabis* and cannabinoids do not occur.[1-4] However, cannabinoid receptors are present in other tissues throughout the body, not just in the central nervous system, and adverse effects include tachycardia, hypotension, conjunctival injection, bronchodilation, muscle relaxation, and decreased gastrointestinal motility.

Although cannabinoids are considered by some to be addictive drugs, their addictive potential is

considerably lower than that of other prescribed agents or substances of abuse.[2,4] The brain develops a tolerance to cannabinoids.

Withdrawal symptoms such as irritability, insomnia with sleep electroencephalogram disturbance, restlessness, hot flashes, and, rarely, nausea and cramping have been observed. However, these symptoms appear to be mild compared with withdrawal symptoms associated with opiates or benzodiazepines, and the symptoms usually dissipate after a few days.

Unlike other commonly used drugs, cannabinoids are stored in adipose tissue and excreted at a low rate (half-life 1–3 days), so even abrupt cessation of cannabinoid intake is not associated with rapid declines in plasma concentrations that would precipitate severe or abrupt withdrawal symptoms or drug cravings.

Since *Cannabis* smoke contains many of the same components as tobacco smoke, there are valid concerns about the adverse pulmonary effects of inhaled *Cannabis*. A longitudinal study in a noncancer population evaluated repeated measurements of pulmonary function over 20 years in 5,115 men and women whose smoking histories were known.[5] While tobacco exposure was associated with decreased pulmonary function, the investigators concluded that occasional and low-cumulative *Cannabis* use was not associated with adverse effects on pulmonary function (forced expiratory volume in the first second of expiration [FEV₁] and forced vital capacity [FVC]).

References

1. Adams IB, Martin BR: Cannabis: pharmacology and toxicology in animals and humans. *Addiction* 91 (11): 1585-614, 1996. [PUBMED Abstract]
2. Grotenhermen F, Russo E, eds.: *Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential*. Binghamton, NY: The Haworth Press, 2002.
3. Sutton IR, Daeninck P: Cannabinoids in the management of intractable chemotherapy-induced nausea and vomiting and cancer-related pain. *J Support Oncol* 4 (10): 531-5, 2006 Nov-Dec. [PUBMED Abstract]
4. Guzmán M: Cannabinoids: potential anticancer agents. *Nat Rev Cancer* 3 (10): 745-55, 2003. [PUBMED Abstract]
5. Pletcher MJ, Vittinghoff E, Kalhan R, et al.: Association between marijuana exposure and pulmonary function over 20 years. *JAMA* 307 (2): 173-81, 2012. [PUBMED Abstract]

Summary of the Evidence for Cannabis and Cannabinoids

To assist readers in evaluating the results of human studies of complementary and alternative medicine (CAM) treatments for people with cancer, the strength of the evidence (i.e., the levels of evidence) associated with each type of treatment is provided whenever possible. To qualify for a level of evidence analysis, a study must:

- Be published in a peer-reviewed scientific journal.
- Report on therapeutic outcome or outcomes, such as tumor response, improvement in survival, or measured improvement in quality of life.

- Describe clinical findings in sufficient detail for a meaningful evaluation to be made.

Separate levels of evidence scores are assigned to qualifying human studies on the basis of statistical strength of the study design and scientific strength of the treatment outcomes (i.e., endpoints) measured. The resulting two scores are then combined to produce an overall score. An overall level of evidence score cannot be assigned to cannabinoids because there has been insufficient clinical research to date. For an explanation of possible scores and additional information about levels of evidence analysis of CAM treatments for people with cancer, refer to Levels of Evidence for Human Studies of Cancer Complementary and Alternative Medicine.

Cannabinoids

Several controlled clinical trials have been performed, and meta-analyses of these support a beneficial effect of cannabinoids (dronabinol and nabilone) on chemotherapy-induced nausea and vomiting (N/V) compared with placebo. Both dronabinol and nabilone are approved by the U.S. Food and Drug Administration for the prevention or treatment of chemotherapy-induced N/V in cancer patients but not for other symptom management or off-label use.

Cannabis

- There have been only three small clinical trials on the use of *Cannabis* in cancer patients. All three studies assessed antiemetic activity but each explored a different patient population and chemotherapy regimen. One study demonstrated no effect, the second study showed a positive effect versus placebo, and the report of the third study did not provide enough information to characterize the overall outcome as positive or neutral. Consequently, there are insufficient data to provide an overall level of evidence assessment for the use of *Cannabis* for chemotherapy-induced N/V. Apparently, there are no published data on the use of *Cannabis* for other cancer-related or cancer treatment-related symptoms.
- An increasing number of trials are evaluating the oromucosal administration of whole *Cannabis* plant extract with fixed concentrations of cannabinoid components.
- At present, there is insufficient evidence to recommend inhaling *Cannabis* as a treatment for cancer-related symptoms or cancer treatment-related side effects.

Changes to This Summary (12/17/2014)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Editorial changes were made to this summary.

This summary is written and maintained by the PDQ Cancer Complementary and Alternative Medicine Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.

About This PDQ Summary

Purpose of This Summary

This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the use of Cannabis and cannabinoids in the treatment of people with cancer. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.

Reviewers and Updates

This summary is reviewed regularly and updated as necessary by the PDQ Cancer Complementary and Alternative Medicine Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).

Board members review recently published articles each month to determine whether an article should:

- be discussed at a meeting,
- be cited with text, or
- replace or update an existing article that is already cited.

Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in the published articles and determine how the article should be included in the summary.

The lead reviewers for Cannabis and Cannabinoids are:

- Donald I. Abrams, MD (UCSF Osher Center for Integrative Medicine)
- Nagi B. Kumar, PhD, RD, FADA (Fellow of the American Dietetic Association)

Any comments or questions about the summary content should be submitted to Cancer.gov through the Web site's Contact Form. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.

Levels of Evidence

Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Cancer Complementary and Alternative Medicine Editorial Board uses a formal evidence ranking system in developing its level-of-evidence designations.

Permission to Use This Summary

PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”

The preferred citation for this PDQ summary is:

National Cancer Institute: PDQ® Cannabis and Cannabinoids. Bethesda, MD: National Cancer Institute.

Date last modified <MM/DD/YYYY>. Available at:

<http://www.cancer.gov/cancertopics/pdq/cam/cannabis/healthprofessional>. Accessed <MM/DD/YYYY>.

Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in Visuals Online, a collection of over 2,000 scientific images.

Disclaimer

The information in these summaries should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the Coping with Cancer: Financial, Insurance, and Legal Information page.

Contact Us

More information about contacting us or receiving help with the Cancer.gov Web site can be found on our Contact Us for Help page. Questions can also be submitted to Cancer.gov through the Web site’s Contact Form.

Updated: December 17, 2014